NASDAQ:MNPR

Monopar Therapeutics (MNPR) Stock Price, News & Analysis

Monopar Therapeutics logo
$69.00 -1.29 (-1.84%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$67.16 -1.84 (-2.67%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Monopar Therapeutics Stock (NASDAQ:MNPR)

Advanced

Key Stats

Today's Range
$67.36
▼
$69.86
50-Day Range
$66.28
▼
$108.32
52-Week Range
$50.07
▼
$124.82
Volume
132,610 shs
Average Volume
153,440 shs
Market Capitalization
$467.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$123.13
Consensus Rating
Moderate Buy

Company Overview

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers.

The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

Monopar is based in the United States and is led by co-founder and Chief Executive Officer Chandler Robinson. Its work is focused on research and clinical development rather than marketing approved products.

AI Generated. May Contain Errors.

Monopar Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

MNPR MarketRank™: 
2.69375 of 5 stars

Monopar Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 421st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Monopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Monopar Therapeutics has a consensus price target of $123.13, representing about 78.4% upside from its current price of $69.00.

  • Amount of Analyst Coverage

    Monopar Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Monopar Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Monopar Therapeutics are expected to decrease in the coming year, from ($2.64) to ($5.19) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Monopar Therapeutics is -28.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Monopar Therapeutics is -28.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Monopar Therapeutics has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    18.21% of the float of Monopar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monopar Therapeutics has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Monopar Therapeutics has recently decreased by 2.22%, indicating that investor sentiment is improving.
  • Dividend Yield

    Monopar Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Monopar Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Monopar Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Monopar Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for MNPR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Monopar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,527,913.00 in company stock.

  • Percentage Held by Insiders

    9.70% of the stock of Monopar Therapeutics is held by insiders.

  • Percentage Held by Institutions

    1.83% of the stock of Monopar Therapeutics is held by institutions.

  • Read more about Monopar Therapeutics' insider trading history.
Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MNPR Stock News Headlines

Brookline Capital Markets Weighs in on MNPR FY2026 Earnings
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
Q1 Earnings Forecast for MNPR Issued By HC Wainwright
See More Headlines

MNPR Stock Analysis - Frequently Asked Questions

Monopar Therapeutics' stock was trading at $65.30 at the start of the year. Since then, MNPR stock has increased by 5.7% and is now trading at $69.00.

Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.00.

Monopar Therapeutics shares reverse split on Tuesday, August 13th 2024.The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Monopar Therapeutics subsidiaries include these companies: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.

Monopar Therapeutics (MNPR) raised $9 million in an initial public offering (IPO) on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager.

Top institutional shareholders of Monopar Therapeutics include State Street Corp (3.42%), Candriam S.C.A. (1.93%), Goldman Sachs Group Inc. (1.31%) and American Century Companies Inc. (0.08%). Insiders that own company stock include Tactic Pharma Llc, Chandler Robinson, Andrew Cittadine, Raymond Anderson, Christopher M Starr, Karthik Radhakrishnan, Quan Anh Vu and Kim R Tsuchimoto.
View institutional ownership trends
.

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), SoundHound AI (SOUN), NIO (NIO), Palantir Technologies (PLTR), Viking Therapeutics (VKTX), BigBear.ai (BBAI) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/12/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MNPR
CIK
1645469
Fax
N/A
Employees
22
Year Founded
2014

Price Target and Rating

High Price Target
$145.00
Low Price Target
$100.00
Potential Upside/Downside
+78.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.72 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-15.52%
Return on Assets
-15.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
43.56
Quick Ratio
43.56

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$18.75 per share
Price / Book
3.68

Miscellaneous

Outstanding Shares
6,780,000
Free Float
6,120,000
Market Cap
$467.82 million
Optionable
Not Optionable
Beta
1.62

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:MNPR) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners